Incyte Corp. closed 18.70% short of its 52-week high of $83.95, which the company achieved on November 8th.

Incyte Corp. closed 16.64% below its 52-week high of $83.95, which the company achieved on November 8th.

After resolving a patent dispute with Incyte, Sun Pharma has officially launched its JAK inhibitor Leqselvi in the U.S. | Sun ...

India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the ...

Sun Pharmaceutical Industries has reached a settlement agreement with Incyte Corporation concerning Leqselvi, a drug for ...

Sun Pharma and Incyte Corporation have settled a legal dispute over Leqselvi, a drug used for severe hair loss. Sun has ...

Sun Pharmaceutical Industries has reached a settlement with Incyte Corporation regarding the Leqselvi drug, used for severe ...

Incyte Corporation (INCY) is a Wilmington, Delaware–based global biopharmaceutical company focused on developing and ...

Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 29, 2025.

Incyte Corporation (NASDAQ:INCY) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio.

Incyte named former Karuna Therapeutics and Anthos Therapeutics exec Bill Meury as CEO. Vistagen appoints Elissa Cote as chief corporate development officer. Inizio Evoke, a 2025 MM+M Agency 100 ...

Incyte's new CEO, Bill Meury, signals a potential strategic pivot toward M&A, leveraging his biopharma acquisition experience ...